Science 37

Science 37 was founded in 2014{{cite web|url=https://venturebeat.com/2017/04/25/science-37-raises-29-million-to-bring-clinical-trials-to-the-home/|title=GV joins $29 million investment into Science 37 to bring clinical trials to the home|date=25 April 2017|publisher=Venture Beat}} by Noah Craft and Belinda Tan, working out of LA BioMed at Harbor-UCLA Medical Center.{{cite web|url=http://labusinessjournal.com/news/2018/mar/07/science-37-novartis-conduct-virtual-clinical-trial/|title=Science 37, Novartis to Conduct Virtual Clinical Trials |publisher=Los Angeles Business Journal|website=labusinessjournal.com}}

Their team developed the Network Oriented Research Assistant platform, also known as the NORA platform, which includes video chat, digital self-photography, data collection, and electronic consent. Together, these features were used to conduct “site-less” trials.

The platform also aided researchers in finding and contacting potential participants, and scheduling trial participants for in-home activities like questionnaires, mobile nurse visits,{{cite journal|last=Landhuis|first=Esther|date=1 April 2018|title=Outsourcing is in|journal=Nature|volume=556|issue=7700|pages=263–265|bibcode=2018Natur.556..263L|doi=10.1038/d41586-018-04163-8|pmid=29643487|doi-access=}} and door-step study medicine delivery.{{cite web|last=Herper|first=Matthew|title=AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz|url=https://www.forbes.com/sites/matthewherper/2018/03/26/ai-telemedicine-quantum-new-novartis-boss-says-tech-will-finally-change-the-drug-biz/#342403e06b54|work=Forbes}}

Science 37 received its initial round of funding in 2015, with a $6.5 million investment, co-led by Lux Capital and dRx Capital.{{cite web|url=https://www.outsourcing-pharma.com/Article/2015/10/26/Novartis-JV-helps-virtual-trial-CRO-to-6.5m-fundraising-round|title=Novartis joint venture helps virtual trial CRO to $6.5m fundraising round|publisher=Outsourcing Pharmaceuticals}} In 2016 the company's second round of financing resulted in $31 million in funding, and a 2017 round of financing resulted in $29 million.{{cite web|url=https://techcrunch.com/2017/04/25/science37-aims-to-democratize-clinical-research-with-a-fresh-29-million-in-growth-funding/|title=Science37 aims to democratize clinical research with a fresh $29 million in growth funding |publisher=TechCrunch|website=techcrunch.com}}{{cite web|url=https://www.outsourcing-pharma.com/Article/2018/03/07/Novartis-scaling-site-less-trials-through-expanded-Science-37-alliance|title=Novartis scaling 'site-less' trials through expanded Science 37 alliance|publisher=}} In March 2019, Science 37 secured $35 million in Series D funding; and announced a leadership transition with David Coman coming in as CEO in November 2019.

In August 2020 Science 37 closed an oversubscribed Series D $40 million funding round led by Lux Capital, Redmile Group and PPD, Inc. (other investors: Novartis, Amgen, Sanofi Ventures, GV, Glynn Capital, LifeSci Ventures and Mubadala Ventures). In May 2021, Science 37 announced that they are to become publicly listed via merger with LifeSci Acquisition II Corp.{{cn|date=June 2023}}

In 2015 Science 37 began working with Genentech in the recruitment of trial participants.{{cite web|url=https://medcitynews.com/2017/08/heres-clinical-trial-utopia-may-look-like/?rf=1|title=Here's what clinical trial utopia may look like |publisher=MedCity News|website=medcitynews.com}} In 2017 Science 37 then completed a site-less trial for AOBiome Therapeutics. This was the first “interventional, randomized, placebo-controlled trial” to be completed virtually.{{cite web|url=http://www.mobihealthnews.com/content/science-37-concludes-its-first-fully-virtual-clinical-trial|title=Science 37 concludes its first fully virtual clinical trial|date=24 October 2017|publisher=Mobile Health News}} That year Science 37 also began planning site-less trials for Sanofi{{cite web|url=https://www.fiercebiotech.com/cro/sanofi-launches-new-virtual-trials-offering-science-37|title=Sanofi launches new virtual trials offering with Science 37 |publisher=FierceBiotech|website=www.fiercebiotech.com}} and Otsuka Pharmaceutical.{{cite web|url=http://www.mobihealthnews.com/content/otsuka-works-science-37-and-more-digital-health-deals|title=Otsuka works with Science 37 and more digital health deals|date=8 December 2017|publisher=Mobile Health News}}

In 2018 the company partnered with Novartis to plan several site-less clinical trials. Novartis also owns 10% of Science 37 from an early-stage investment in the company.{{cite web|url=https://endpts.com/novartis-joins-forces-with-la-tech-company-science-37-to-launch-virtual-clinical-trials/|title=Novartis joins forces with LA tech company Science 37 to launch virtual clinical trials|website=endpts.com}} Science 37 was already in the process of conducting trials with Novartis in acne, cluster headaches, and fatty liver disease.

{{reflist}}

• [https://www.science37.com/ Official website]

Category:Medical and health organizations based in California

Category:2014 establishments in California

Category:Companies formerly listed on the Nasdaq

Category:2024 mergers and acquisitions